RxDoctor Payments Data

Kris Kumar

Interventional Cardiology · Portland, ORNPI 1003294968

Payments from drug & device makers

What this record shows

This record is dominated by grants: $18,349 of the $21,694 with a category attached, or 84.6%. 16 manufacturers reported payments, led by Boston Scientific at 48.6% of the total. Reporting peaked in 2023 at $15,396 and has fallen 98.4% since, to $246 in 2025.

$21,694in general payments, 2019–2025

Across 46 payments — averaging $471.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$11K
  • Medtronic$8K
  • Abbott$2K
  • Edwards Lifesciences$438
  • Abiomed$196
  • Terumo Medical Corporation$142
  • plus $572 from 10 others
$150in research payments, 2019–2025

Across 2 payments — averaging $75.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$150

What the payments were for

  • Grants$18,34985%
  • Travel & lodging$1,2706%
  • Food & beverage$1,9989%
  • Education$760%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,694 in reported general payments places this provider in the 75th percentile of 68 interventional cardiology providers in Oregon.

See all interventional cardiology providers in Oregon

Medicare billing

Part B allowed, 2024
$21,798
Medicare patients
242
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$13,324
ClopidogrelClopidogrel Bisulfate44$438
Atorvastatin Calcium23$263
Metoprolol Succinate13$119
Furosemide12$69

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →